Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Charles River Laboratories International, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$270.95 |
52 Week High | US$275.00 |
52 Week Low | US$161.65 |
Beta | 1.39 |
1 Month Change | 7.12% |
3 Month Change | 14.62% |
1 Year Change | 36.82% |
3 Year Change | -7.89% |
5 Year Change | 88.30% |
Change since IPO | 1,131.59% |
Recent News & Updates
Recent updates
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Charles River acquires SAMDI Tech for $50M in cash
Jan 30Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?
Jan 24If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity
Jan 10Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital
Jan 05We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Dec 14Charles River Laboratories Non-GAAP EPS of $2.63 beats by $0.13, revenue of $989.2M beats by $18.77M, updates FY guidance
Nov 02Charles River Laboratories: Near-Term Headwinds Outweigh Long-Term Tailwinds
Oct 18Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?
Oct 18Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Oct 04Charles River raised to Buy at Jefferies on prospects for animal studies
Sep 30Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Sep 21Charles River Laboratories: A 'Picks And Shovels' Biomedical Play, Now Attractively Priced
Sep 10Is Now The Time To Look At Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Sep 07Charles River Laboratories hits new 52-week low; shares down 43% YTD
Aug 30Shareholder Returns
CRL | US Life Sciences | US Market | |
---|---|---|---|
7D | -0.9% | -0.2% | 0.4% |
1Y | 36.8% | 4.5% | 28.8% |
Return vs Industry: CRL exceeded the US Life Sciences industry which returned 4.5% over the past year.
Return vs Market: CRL exceeded the US Market which returned 28.8% over the past year.
Price Volatility
CRL volatility | |
---|---|
CRL Average Weekly Movement | 5.1% |
Life Sciences Industry Average Movement | 7.3% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRL has not had significant price volatility in the past 3 months.
Volatility Over Time: CRL's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1947 | 21,100 | Jim Foster | https://www.criver.com |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Charles River Laboratories International, Inc. Fundamentals Summary
CRL fundamental statistics | |
---|---|
Market cap | US$13.83b |
Earnings (TTM) | US$474.62m |
Revenue (TTM) | US$4.13b |
29.3x
P/E Ratio3.4x
P/S RatioIs CRL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRL income statement (TTM) | |
---|---|
Revenue | US$4.13b |
Cost of Revenue | US$2.60b |
Gross Profit | US$1.53b |
Other Expenses | US$1.05b |
Earnings | US$474.62m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 9.24 |
Gross Margin | 37.03% |
Net Profit Margin | 11.49% |
Debt/Equity Ratio | 71.7% |
How did CRL perform over the long term?
See historical performance and comparison